Natera stock raises 2026 outlook as test volumes accelerate

Natera reported strong third-quarter growth on Thursday, November 5, while higher investment in staffing and clinical trials added pressure to its cost base. The company raised its full-year revenue outlook and completed a leadership transition to Solomon Moshkevich.

In a November 5 release published by Business Wire, Natera said third-quarter revenue reached 794.0 million US dollars, up 34.1 percent from the year-earlier period. Test processing rose 22.3 percent to 1,093,100, while oncology tests increased 60.9 percent to 339,500.

Investment Raises Execution Demands

Total operating expenses increased 19.5 percent to 576.1 million US dollars. Natera attributed the increase primarily to headcount growth supporting new products and higher clinical-trial expenses. The company still reduced its quarterly net loss to 59.9 million US dollars, or 0.42 US dollars per diluted share, from 87.5 million US dollars, or 0.64 US dollars per share, a year earlier.

Natera lifted its 2026 revenue outlook to 3.005 billion to 3.035 billion US dollars from 2.850 billion to 2.910 billion US dollars, raising the midpoint by 140 million US dollars. The company expects a gross margin of 64 percent to 66 percent, selling, general and administrative costs of 1.225 billion to 1.300 billion US dollars, research and development costs of 825 million to 925 million US dollars, and positive cash flow.

Leadership Change Adds A New Test

Moshkevich took over as chief executive immediately after Steve Chapman stepped down. Chapman remains a consultant and board adviser, providing continuity as Natera invests in oncology testing, clinical studies and new product offerings.

Natera stock traded at 286.75 euros on Lang & Schwarz at 16:09 CET on Tuesday, November 10, 2026.

The S&P 500 market environment remains relevant for investors assessing risk appetite around growth-oriented healthcare stocks.

More news and analyses on Natera stock